2022
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trials
2021
Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial
Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. Circulation Heart Failure 2021, 14: e007034. PMID: 33530704, PMCID: PMC7908815, DOI: 10.1161/circheartfailure.120.007034.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsCardiotonic AgentsCardiovascular DiseasesChronic DiseaseDrug CombinationsEnalaprilGlomerular Filtration RateHeart FailureHospitalizationHumansHyperkalemiaHypotensionIntensive Care UnitsNatriuretic Peptide, BrainPeptide FragmentsRenal InsufficiencyRiskValsartanConceptsAcute decompensated heart failureSacubitril/valsartanDecompensated heart failureHeart failureCardiovascular deathHigh-risk subpopulationsIndex hospitalizationSymptomatic hypotensionRenal functionSafety outcomesBaseline systolic blood pressureBaseline NT-proBNPPIONEER-HF trialDouble-blind trialHigh-risk patientsGlomerular filtration rateSystolic blood pressureHigh-risk subgroupsRelative risk reductionRisk-benefit profileLow-risk subgroupsHospital initiationInotrope usePIONEER-HFNT-proBNP